USPTO serial 79345356
OCLAIZ
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 23, 2024
- Examiner
- BULLOFF, TOBY ELLEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OCLAIZ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Kreider Gaunt
Karen Kreider Gaunt Dinsmore & Shohl LLP255 E. 5th St, Suite 1900Cincinnati, OH 45202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone | ACTIVE | — |
| 010 | Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Camurus AB
- Other trademarks owned by Camurus AB
- Other trademarks owned by Camurus AB
- Other trademarks owned by Camurus AB
- Other trademarks owned by Camurus AB
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named OCLAIZ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 14, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Dec 4, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 4, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 4, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 4, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 4, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 13, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 24, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 24, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 23, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 23, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 23, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 13, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 27, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 27, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 7, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 7, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 6, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 18, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 18, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 18, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 4, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 3, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 2, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 2, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 24, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 25, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 5, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 5, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 17, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 16, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 15, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 26, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 22, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 21, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |